ADMA Biologics Inc Revenue 2013-2021 | ADMA

ADMA Biologics Inc revenue from 2013 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
ADMA Biologics Inc Annual Revenue
(Millions of US $)
2020 $42
2019 $29
2018 $17
2017 $23
2016 $11
2015 $7
2014 $6
2013 $3
2012 $1
ADMA Biologics Inc Quarterly Revenue
(Millions of US $)
2021-09-30 $21
2021-06-30 $18
2021-03-31 $16
2020-12-31 $14
2020-09-30 $10
2020-06-30 $8
2020-03-31 $10
2019-12-31 $12
2019-09-30 $7
2019-06-30 $7
2019-03-31 $4
2018-12-31 $4
2018-09-30 $4
2018-06-30 $5
2018-03-31 $4
2017-12-31 $12
2017-09-30 $5
2017-06-30 $3
2017-03-31 $3
2016-12-31 $3
2016-09-30 $3
2016-06-30 $2
2016-03-31 $2
2015-12-31 $3
2015-09-30 $2
2015-06-30 $1
2015-03-31 $2
2014-12-31 $1
2014-09-30 $1
2014-06-30 $2
2014-03-31 $2
2013-12-31 $0
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.272B $0.042B
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $138.972B 8.78
Bio-Rad Laboratories (BIO.B) United States $16.992B 34.48
QIAGEN (QGEN) Netherlands $11.128B 18.85
Biohaven Pharmaceutical Holding (BHVN) United States $7.780B 0.00
Emergent Biosolutions (EBS) United States $2.486B 8.94
Arcus Biosciences (RCUS) United States $2.230B 0.00
Myovant Sciences (MYOV) United Kingdom $1.231B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.064B 0.00
Zymeworks (ZYME) Canada $0.466B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Ambrx Biopharma (AMAM) United States $0.193B 0.00
Enzo Biochem (ENZ) United States $0.153B 19.75